Table 3.
Clinical characteristics stratified by ABPA and fungus group
| Rare + ABPA (N = 27) | Rare no ABPA (N = 154) | Frequent + ABPA (N = 20) | Frequent no ABPA (N = 93) | p value | |
|---|---|---|---|---|---|
| Age (in years) follow‐up, median (range) | 15.1 9.4–20.5 | 15.4 6.4–46.1 | 16.0 13.2–55.2 | 16.7 7.9–35.6 | .03 |
| Average ppFEV1 follow‐up, mean (SD) | 82.6 (14.9) | 80.8 (20) | 73.1 (18) | 79 (21.1) | .33 |
| BMI Percentile, mean (SD) | 43 (24.4) | 42.4 (26.7) | 42.2 (28) | 38.5 (24.4) | .67 |
| Co‐morbidities during follow‐up time, n (%) | |||||
| Asthma | 15 (55.6) | 47 (30.7) | 16 (80.0) | 30 (31.9) | .04 |
| CFRD | 8 (44.4) | 32 (32.0) | 11 (75.0) | 19 (26.6) | .79 |
| Co‐morbidities ever diagnosed, n (%) | |||||
| Asthma | 22 (81.5) | 86 (55.8) | 18 (90.0) | 45 (48.4) | <.01 |
| CFRD | 12 (44.4) | 49 (31.8) | 15 (75.0) | 25 (26.9) | <.01 |
| Co‐infections, n (%) | |||||
| Chronic Pa | 8 (29.6) | 59 (38.6) | 12 (60.0) | 46 (49.5) | .07 |
| Ever Pa positive | 16 (59.3) | 78 (50.6) | 18 (90.0) | 64 (68.8) | <.01 |
| S. maltophilia | 12 (44.4) | 42 (27.5) | 14 (70.0) | 39 (41.5) | <.01 |
| IgE, kUA/L mean (SD) | 830 (696) | 117 (240) | 987 (1115) | 123 (154) | <.01 |
| Eosinophils, absolute 103/mcl, mean (SD) | 0.39 (0.28) | 0.21 (0.13) | 0.39 (0.24) | 0.21 (0.10) | <.01 |
| Admissions, per year, mean (SD) | 1.58 (0.59) | 1.56 (0.84) | 1.97 (0.78) | 1.78 (1.44) | .35 |
Note: p = value determined by ANOVAs or Chi‐squared tests, p < .05 statistically significant. Ever Pa Positive was defined as ever isolating Pa on at least one occasion during the follow‐up period. Group during follow‐up was defined as the number of individuals that continued to have at least one rare or frequent year in the follow‐up period.
Abbreviations: ANOVA, analysis of variance; ABPA, allergic bronchopulmonary aspergillosis; BAL, bronchoalveolar lavage fluid; BMI, body mass index; CFRD, CF related diabetes; IgE, immunoglobulin E; MRSA, methicillin resistant Staphylococcus aureus; MSSA, methicillin sensitive Staphylococcus aureus; OP, oropharyngeal swab; Pa, Pseudomonas aeruginosa; ppFEV1, percent predicted forced expiratory volume in 1 s; S. maltophilia, Stenotrophomonas maltophilia.